McEntee W J, Crook T H
Memory Assessment Clinics Inc., Sarasota, FL 34239.
Neurology. 1990 Mar;40(3 Pt 1):526-30. doi: 10.1212/wnl.40.3_part_1.526.
Age-associated memory impairment (AAMI) is a recently defined clinical state which describes loss of memory function in otherwise healthy persons age 50 and over. This is a relatively modest cognitive impairment thought to be common enough to be a feature of normal aging. There is considerable interest among memory researchers, and in the pharmaceutical industry, to establish the neurochemical basis and develop effective treatment for this condition. As in studies of dementia, much attention is focused on cholinergic function in relation to AAMI, with less emphasis on other neurochemical systems, such as those containing catecholamines. Diminished catecholamine function is implicated in dementing illness of the aged and may also be important in AAMI. This article proposes a role for catecholamines in AAMI and discusses possible treatment strategies.
年龄相关性记忆损害（AAMI）是一种最近定义的临床状态，描述了50岁及以上其他方面健康的人群记忆功能的丧失。这是一种相对轻度的认知损害，被认为相当常见，是正常衰老的一个特征。记忆研究人员以及制药行业对确定这种情况的神经化学基础并开发有效的治疗方法有着浓厚的兴趣。与痴呆症研究一样，很多注意力都集中在与AAMI相关的胆碱能功能上，而对其他神经化学系统，如含有儿茶酚胺的系统的关注较少。儿茶酚胺功能减退与老年痴呆症有关，在AAMI中可能也很重要。本文提出了儿茶酚胺在AAMI中的作用，并讨论了可能的治疗策略。
